H&R REIT calls special unitholders meeting on proposed GO Residential deal
Bitget2026/10/08 12:02H&R Real Estate Investment Trust will hold a virtual special meeting on Nov. 13, 2026. Unitholders will vote on an arrangement under which GO Residential REIT and a buyer group would acquire all H&R assets. The deal offers CAD 4.28 in cash per unit, expected 0.5688 GO REIT unit per H&R unit. Total consideration was valued at CAD 12.01 per unit using GO REIT’s Aug. 10, 2026 close and a 1.3942 FX rate. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. H&R Real Estate Investment Trust published the original content used to generate this news brief via CNW (Ref. ID: 202610080800CANADANWCANADAPR_C3796) on October 08, 2026, and is solely responsible for the information contained therein.
- H&R Real Estate Investment Trust will hold a virtual special meeting on Nov. 13, 2026.
- Unitholders will vote on an arrangement under which GO Residential REIT and a buyer group would acquire all H&R assets.
- The deal offers CAD 4.28 in cash per unit, expected 0.5688 GO REIT unit per H&R unit.
- Total consideration was valued at CAD 12.01 per unit using GO REIT’s Aug. 10, 2026 close and a 1.3942 FX rate.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
